JPM deals, policy outlook and trends in FDA approvals

A view of financing and partnership activity at biotech’s annual kickoff event

Riding the tailwind of a strong 2H25, the days leading up to biotech’s annual kickoff meeting in San Francisco delivered billions in capital raised and more than two dozen deals announced. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss two of the largest deals announced at the start of the J.P. Morgan Healthcare Conference, a partnership for a bispecific between AbbVie Inc. (NYSE:ABBV) and RemeGen Co. Ltd. (HKEX:9995) and the launch of “NewCo” AirNexus Therapeutics by  Haisco Pharmaceutical Group Co. Ltd. (SZSE:002653) and a syndicate led by Frazier Life Sciences.

The analysts also discuss Washington Editor Steve Usdin’s policy outlook for the year ahead, and Executive Director of Biopharma Intelligence Lauren Martz’s analysis of trends in FDA’s 2025 approvals.